Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Kenji ZennamiMakoto SumitomoKiyoshi TakaharaTakuhisa NukayaMasashi TakenakaKosuke FukayaManabu IchinoNaohiko FukamiHitomi SasakiMamoru KusakaRyoichi ShirokiPublished in: BJU international (2020)
Two cycles of NAC improved the survival of patients with high-risk UTUC, even in patients with localised disease. Although two cycles of NAC appear to be effective in cN0M0 high-risk UTUC including localised disease, additional larger sample size multicentre prospective studies comparing short-course NAC regimens followed by surgery and surgery alone are required.